Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired (Tables)

Licenses Acquired (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of research and development-licenses



	Three Months Ended September 30,				Nine Months Ended September 30,
($ in thousands)	2020		2019		2020		2019
Partner companies:
Mustang	$	287	$	700	$	1,837	$	1,350
Aevitas		162		—		162		—
Baergic		8		—		8		—
Oncogenuity		1		—		271		—
Total	$	458	$	700	$	2,278	$	1,350

Schedule of research and development for licenses acquired

For the three and nine months ended September 30, 2020 and 2019, Mustang recorded the following expense in research and development for licenses acquired:


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
($ in thousands)	2020		2019		2020		2019
City of Hope National Medical Center
CD123 (MB-102)³	$	—	$	—	$	334	$	250
IL13Rα2 (MB-101)³		—		—		333		—
HER2 (MB-103)¹		—		—		250		—
CS1 (MB-104)		—		—		—		200
PSCA (Spacer)³		—		200		333		200
Fred Hutch - CD20 (MB-106)²		—		—		300		—
Nationwide Children’s Hospital - C134 (MB-108)		—		—		—		200
CSL Behring (Calimmune)		170		200		170		200
UCLA		—		300		—		300
SIRION LentiBOOST^TM		117		—		117		—
Total	$	287	$	700	$	1,837	$	1,350

Note 1:

Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-103 at COH, for the nine months ended September 30, 2020.

Note 2:

Represents a non-refundable milestone payment in connection with the twelth patient treated in the Phase 1 clinical study of MB-106 at Fred Hutch, for the nine months ended September 30, 2020.

Note 3:

Represents a milestone payment to COH in connection with Mustang’s public underwritten offerings, for the nine months ended September 30, 2020.